Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2021-055596
PubMed Identifier: 35260458
Publication URI: http://europepmc.org/abstract/MED/35260458
Type: Journal Article/Review
Parent Publication: BMJ Open
Issue: 3
ISSN: 2044-6055